FDA Orange Book · active-ingredient family
Levalbuterol tartrate
Levalbuterol tartrate is approved in 1 FDA application, with therapeutic-equivalence codes, listed patents, and marketing exclusivity from the FDA Orange Book.
Reference-listed drug:XOPENEX HFA · NDA 021730
1
Brand (NDA)
0
Generics (ANDA)
0
Listed patents
0
Exclusivity periods
Brand (NDA) products · aerosol, metered
| Product | Applicant | Application | TE | Approved | |
|---|---|---|---|---|---|
| XOPENEX HFARLD | LUPIN | NDA 021730 | — | Mar 11, 2005 |
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
Levalbuterol tartrate — frequently asked questions
Generics, reference-listed drug, patents, and exclusivity for this active ingredient, from the FDA Orange Book.

